Drugs / SENREBOTASE
SENREBOTASE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01678924 | Jan 2013 → May 2015 | postherpetic neuralgia | Allergan | Terminated | No outcome recorded |
| Phase 2 | NCT01157377 | Oct 2010 → Feb 2013 | overactive bladder | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01129531 | Jun 2010 → Oct 2011 | postherpetic neuralgia | Allergan | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SENREBOTASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137348 ↗ |
| Known as | AGN-214868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01157377 ↗ |
| Known as | Senrebotasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137348 ↗ |
| Known as | SXN-100323 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137348 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3137348 ↗ |
| Route | Other | “AGN-214868 injected into the bladder.” NCT01157377 ↗ |